Last update: July 6, 2018
Minimal risk for breastfeeding and infant.
An antihistamine and inhibitor of the release of proinflammatory mediators from mast cells.
Indicated in conjunctivitis and allergic rhinitis.
Topical administration, twice a day.
Since the date of last update, we have not found published data on its excretion in breastmilk.
As in most topical ophthalmological and nasal preparations, the minute dose and its negligible transfer into blood makes it compatible with breastfeeding.
Ophthalmic administration results in plasma concentrations that are very low or below the limit of quantification (EMA 2017, Meier 2017), which makes the transfer in significant amounts to breastmilk very unlikely.
Nasal absorption is greater, similar to oral absorption (57% bioavailability) (Chu 2009).
There are no cumulative effects after multiple doses (Meier 2017, Chu 2009) and side effects are not frequent or serious (EMA 2017).
In ophthalmic administration, absorption can be minimized by pressing a finger on the tear duct (medial canthus of the eye) for 1 minute.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine from United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM